Fibrocor Therapeutics

#Collaboration #Fibrocor Therapeutics #Monoclonal antibodies #Phase I trial

New R&D collaboration to advance Alport Syndrome programme

Fibrocor Therapeutics has entered into a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome programme. The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies… Read More

#Business & Investment #News

Fibrosis lungs
#Fibrocor Therapeutics #Fibrosis #Fibrotic disease #Small molecules #Therapeutics

Fibrosis research: Advances and challenges 

Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research.   MT:… Read More

#Exclusive Content #Opinion